Health Care • Other Pharmaceuticals
$250.48 ▼ -0.61
(-0.24%)
MKT CAP: $58.14B • VOL: 1.95M
52W L $180 52W H $260
CAH // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-06-30 | FY 2024
FILED 2024-06-30 | FY 2023
FILED 2023-06-30 |
|---|---|---|---|
| Revenue (Total Sales) | $222.58B | $226.83B | $204.98B |
| YoY Revenue Growth % | -1.9% | +10.7% | — |
| Gross Profit | $8.17B | $7.41B | — |
| Gross Margin % | 3.7% | 3.3% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $2.27B | $1.24B | $752.0M |
| Operating Margin % | 1.0% | 0.5% | 0.4% |
| Net Income (GAAP) | $1.56B | $852.0M | $330.0M |
| EBITDA (Normalized) | $2.71B | $1.65B | $8.13B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $2.40B | $3.76B | $2.84B |
| Capital Expenditures (CapEx) | $547.0M | $511.0M | $9.22B |
| Free Cash Flow (FCF) | $1.85B | $3.25B | -$6.38B |
| FCF Margin % | 0.8% | 1.4% | -3.1% |
| Return on Invested Capital (ROIC %) | 22.7% | 23.4% | 0.4% |
| Cash & Short-Term Equivalents | $2.78B | $3.81B | — |
| Total Debt (Short + Long Term) | $13.59B | $11.00B | $57.56B |
| Total Stockholders' Equity | -$2.88B | -$2.99B | $118.07B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CAH.